CONTEXT THERAPEUTICS INC (CNTX) competitors & alternatives
Health Care · NASDAQ
CONTEXT THERAPEUTICS INC (CNTX)'s top competitors and alternatives — its most similar public companies — include Amgen (AMGN), Regeneron Pharmaceuticals (REGN), CG ONCOLOGY INC (CGON), XENCOR INC (XNCR), CRESCENT BIOPHARMA INC (CBIO), COMPASS THERAPEUTICS (CMPX), JANUX THERAPEUTICS INC (JANX), Summit Therapeutics (SMMT), Hemab Therapeutics Holdings, Inc. (COAG), REPLIMUNE GROUP INC (REPL), Cue Biopharma, Inc. (CUE) and ERASCA INC (ERAS). These are CONTEXT THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CNTX competitors & alternatives
-
AmgenAMGNHealth Care
A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone…
$366.05 (as of 2026-07-22) · market cap $197.7B
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
CG ONCOLOGY INCCGONHealth Care
An early-stage immuno-oncology company developing cretostimogene, a novel therapeutic candidate for high-risk and intermediate-risk non-muscle-invasive bladder…
$69.31 (as of 2026-07-22) · market cap $6.3B
-
XENCOR INCXNCRHealth Care
Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific…
$19.51 (as of 2026-07-22) · market cap $1.4B
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
COMPASS THERAPEUTICSCMPXHealth Care
Compass Therapeutics is a clinical-stage oncology company developing a pipeline of bispecific and agonistic antibodies designed to treat solid tumors by…
$2.04 (as of 2026-07-22) · market cap $367M
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.62 (as of 2026-07-22) · market cap $953M
-
Summit TherapeuticsSMMTHealth Care
Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase…
$14.74 (as of 2026-07-22) · market cap $11.4B
-
Hemab Therapeutics Holdings, Inc.COAGHealth Care
Hemab Therapeutics is a clinical-stage biotechnology company developing innovative bispecific and monovalent antibody therapies for serious, rare blood…
$49.23 (as of 2026-07-22) · market cap $2.3B
-
REPLIMUNE GROUP INCREPLHealth Care
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in…
$10.75 (as of 2026-07-22) · market cap $918M
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$34.20 (as of 2026-07-22) · market cap $144M
-
ERASCA INCERASHealth Care
A precision oncology company developing first-in-class RAS/MAPK pathway-targeting therapies for cancers driven by the most frequently mutated oncogene…
$19.51 (as of 2026-07-22) · market cap $6.8B
Not quite? Describe exactly what you want →
Peers are CONTEXT THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: CONTEXT THERAPEUTICS INC (CNTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.